Tag: Solid Tumors

Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from the Phase 3 SigVie-002 Study

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors

In a statement Pfizer confirmed that it has discontinued the development of felmetatug vedotin (also known as PF-08046048 or SGN-B7H4V; see Drugmap).

German-based Tubulis continues the expansion of its clinical pipeline with a second ADC drug candidate entering the clinic. Earlier this week the company announced the dosing of the first patient in the 5-STAR-1-01 clinical trial evaluating ADC candidate TUB-030 in solid tumors.

A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα / FOLR1)...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to DB-1303 a novel antibody-drug conjugates for the treatment of patients with advanced, recurrent or metastatic endometrial carcinoma with HER2 over-expression who have progressed on or after standard systemic treatment.

An ongoing, phase 1 dose-escalation study investigating XB002, Exelixis’ next-generation tissue factor-targeting antibody-drug conjugate (ADC) for the treatment of patients with advanced solid tumors, has shown promising results.

A first patient has been dosed in a Phase 1 clinical trial evaluating ADCT-901, targeting kidney-associated antigen 1 (KAAG1), in patients with selected advanced...

This week the U.S. Food and Drug Administration (FDA) has granted full approval to Sacituzumab Govitecan* (Trodelvy®; Gilead Sciences) for the treatment of adult...